The role of the Molecular Adsorbents Recirculating System (MARS) in the management of liver failure

Perfusion

Volumn 19, Issue SUPPL. 1, 2004, Pages

  Sen, Sambit ^a   Jalan, Rajiv ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANION EXCHANGE RESIN; CHARCOAL;

BRAIN DYSFUNCTION; CLINICAL TRIAL; DEVICE; DIALYSATE; DIALYSIS; DIALYSIS MEMBRANE; EXTRACORPOREAL CIRCULATION; HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERBILIRUBINEMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER FAILURE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

EID: 2342657996     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1191/0267659104pf716oa     Document Type: Review

References (53)

1. Shakil AO, Kramer D, Mazariegos GV, Fung JJ, Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl 2000; 6: 163-69.
2. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002; 20: 252-61.
3. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002; 22: 5-13.
4. Arroyo V. Review article: albumin in the treatment of liver diseases - new features of a classical treatment. Aliment Pharmacol Ther 2002; 16: 1-5.
5. Ruiz-del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-86.
6. Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-10.
7. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-409.
8. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374-80.
9. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-48.
10. Curry S, Mandelkow H, Brick P, Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 1998; 5: 827-35.
11. Evans TW. Review article: albumin as a drug - biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002; 16: 6-11.
12. Awad SS, Rich PB, Kolla S, et al. Characteristics of an albumin dialysate hemodiafiltration system for the clearance of unconjugated bilirubin. Asaio J 1997; 43: M745-49.
13. Awad SS, Sawada S, Soldes OS, et al. Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system? Asaio J 1999; 45: 47-49.
14. Awad SS, Swaniker F, Magee J, Punch J, Bartlett RH. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001; 130: 354-62.
15. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003; 38: 24-31.
16. Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patient's blood and a bioartificial liver. Int J Artif Organs 1996; 19: 677-91.
17. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993; 17: 809-13.
18. Hughes R, Ton HY, Langley P, et al. Albumin-coated Amberlite XAD-7 resin for hemoperfusion in acute liver failure. Part II: in vivo evaluation. Artif Organs 1979; 3: 23-26.
19. Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. Asaio J 1993; 39: M621-25.
20. Mitzner SR, Klammt S, Peszynski P, et al. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher 2001; 5: 417-22.
21. Sorkine P, Ben Abraham R, Szold O, et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 2001; 29: 1332-36.
22. Stange J, Mitzner SR, Risler T, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999; 23: 319-30.
23. Schmidt LE, Svendsen LB, Sorensen VR, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001; 7: 709-12.
24. Schmidt LE, Sorensen VR, Svendsen LB, Hansen BA, Larsen FS. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl 2001; 7: 1034-39.
25. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-86.
26. Stange J, Mitzner SR, Klammt S, et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl 2000; 6: 603-13.
27. Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36: 949-58.
28. Novelli G, Rossi M, Pretagostini R, et al. MARS (Molecular Adsorbent Recirculating System): experience in 34 cases of acute liver failure. Liver 2002; 22: 43-47.
29. Isoniemi H. Current indications for albumin dialysis: acute hepatic failure. In 4th International Symposium on Albumin Dialysis in Liver Disease, Rostock-Warnemunde, September 2002.
30. Abraham RB, Szold O, Merhav H, et al. Rapid resolution of brain edema and improved cerebral perfusion pressure following the molecular adsorbent recycling system in acute liver failure patients. Transplant Proc 2001; 33: 2897-99.
31. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003; 9: 290-97.
32. Lamesch P, Jost U, Schreiter D, et al. Molecular adsorbant recirculating system in patients with liver failure. Transplant Proc 2001; 33: 3480-82.
33. Manz T, Ochs A, Bisse E, Strey C, Grotz W. Liver support - a task for nephrologists? Extracorporeal treatment of a patient with fulminant Wilson crisis. Blood Purif 2003; 21: 232-36.
34. Sen S, Felldin M, Steiner C, et al. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease. Liver Transpl 2002; 8: 962-67.
35. Kreymann B, Seige M, Schweigart U, Kopp KF, Classen M. Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins. J Hepatol 1999; 31: 1080-85.
36. McIntyre CW, Fluck RJ, Freeman JG, Lambie SH. Use of albumin dialysis in the treatment of hepatic and renal dysfunction due to paracetamol intoxication. Nephrol Dial Transplant 2002; 17: 316-17.
37. Siewert-Delle A, Henriksson BA, Baeckmann L. Albumin dialysis with the MARS for a patient with acute liver failure due to paracetamol intoxication: a case report. Z Gastroenterol 2001; 39: 48.
38. Shi Y, He J, Chen S, et al. MARS: optimistic therapy method in fulminant hepatic failure secondary to cytotoxic mushroom poisoning - a case report. Liver 2002; 22: 78-80.
39. Catalina MV, Nunez O, Ponferrada A, et al. Liver failure due to mushroom poisoning: clinical course and new treatment perspectives. Gastroenterol Hepatol 2003; 26: 417-20.
40. Novelli G, Rossi M, Pretagostini R, et al. Use of MARS in the treatment of acute liver failure: preliminary monocentric experience. Transplant Proc 2001; 33: 1942-44.
41. Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002; 26: 103-10.
42. Kellersmann R, Gassel HJ, Buhler C, Thiede A, Timmermann W. Application of Molecular Adsorbent Recirculating System in patients with severe liver failure after hepatic resection or transplantation: initial single-centre experiences. Liver 2002; 22: 56-58.
43. Mullhaupt B, Kullak-Ublick GA, Ambuhl P, et al. First clinical experience with Molecular Adsorbent Recirculating System (MARS) in six patients with severe acute on chronic liver failure. Liver 2002; 22: 59-62.
44. Delafosse B, Garnier E, Dumortier J, Boillot O. Edouard Herriot experience with the MARS in 5 patients experiencing hepatic failure. Z Gastroenterol 2001; 39: 38.
45. Sturm E, Franssen CF, Gouw A, et al. Extracorporeal albumin dialysis (MARS) improves cholestasis and normalizes low apo A-I levels in a patient with benign recurrent intrahepatic cholestasis (BRIC). Liver 2002; 22: 72-75.
46. Mullhaupt B, Kullak-Ublick GA, Ambuhl PM, Stocker R, Renner EL. Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus. Hepatol Res 2003; 25: 442-6.
47. Doria C, Mandala L, Smith J, et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl 2003; 9: 437-43.
48. Sen S, Jalan R, Morris EC, Steiner C, Mackinnon S, Williams R. Reversal of severe cholestasis caused by chronic graft-versus-host disease with the MARS liver-support device. Transplantation 2003; 75: 1766-67.
49. Notohamiprodjo M, Banayosy A, Kizner L, Schuller V, Korfer R. One year experience with MARS therapy in patients with multiorgan failure in Cardiac Center Bad Oyenhausen. Z Gastroenterol 2001; 39: 51.
50. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Noldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12: S75-82.
51. Sen S, Mookerjee RP, Davies NA, Williams R, Jalan R. Review article: the Molecular Adsorbents Recirculating System (MARS) in liver failure. Aliment Pharmacol Ther 2002; 16: 32-38.
52. Sen S, Davies NA, Mookerjee RP, Cheshire L, Williams R, Jalan R. Pathophysiological basis of clinical changes in acute-on-chronic liver failure following treatment with MARS: a randomized evaluation. In 4th International Symposium on Albumin Dialysis in Liver Disease, Rostock-Warnemunde, September 2002.
53. Sen S, Ratnaraj N, Davies NA, et al. Treatment of phenytoin toxicity by the molecular adsorbents recirculating system (MARS). Epilepsia 2003; 44: 265-67.